Nasdaq apls.

Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […]Nov 22, 2023 · Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […] Nov 29, 2023 · The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16. (APLS) Share Price. NASDAQ. $49.10. As on 17-Nov-2023 16:00 EST. up-down-arrow $1.21 • 2.53%. Prev Close info. $47.89. Day's Open info. $47.74. Today's High ...Nov 30, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

APLS STOCK Price - Apellis Pharmaceuticals Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.Jan 27, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ... Sep 27, 2023 · Shares of Apellis Pharmaceuticals ( APLS 6.66%) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on ...

WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) EPS for the quarter, missing analysts ...

Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. Its revenue was up 400.5% on a year-over-year basis.WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...

For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.

Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis …

Fintel reports that on April 14, 2023, Goldman Sachs maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 9.95% UpsideAPLS Quantitative Stock Analysis. June 27, 2023 — 12:04 pm EDT. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC ( APLS). Of the ...A few examples include what’s going on with shares of Yellow Corp (OTCMKTS:YELLQ), Nio (NYSE: NIO), and Apellis Pharmaceuticals (NASDAQ: APLS) stock today. You can catch up on all of that news ...WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...Find the latest Insider Activity data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. Bill Oxford/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Beam Therapeutics (NASDAQ:BEAM) will collaborate to develop therapies for complement-driven diseases.; The body's ...

Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.STOCKHOLM, Dec. 13, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today new data demonstrating that ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?

APLS Quantitative Stock Analysis. June 27, 2023 — 12:04 pm EDT. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC ( APLS). Of the ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10062500 shares of its common stock at ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Institutional Holdings | Nasdaq Skip to main content Created with Sketch. Market Activity Funds + ETFs After-Hours Quotes …WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ... 1. Ramish Cheema. August 3, 2023 at 9:46 PM · 8 min read. In this piece, we will take a look at ten oversold midcap stocks to buy. If you want to skip an introduction to technical trading and the ...WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...APLS is trading at a 30% discount. Price $53.92. Nov 30, 2023. Fair Value $86.12. Nov 30, 2023 ... Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) saw strong trading volume on Monday . 3,184,166 shares were traded during mid-day trading, an increase of 16% from the previous ...Get 7 Days Free Sign In Sign In Topics

Apellis Pharmaceuticals (NASDAQ: APLS) · Apellis Pharmaceuticals Return vs. S&P · Apellis Pharmaceuticals Company Info · News & Analysis · Financial Health ...

Jul 28, 2023 · As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ...

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ...WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...It is now at its lowest level since June of 2020: 1. That is not a pretty 2-year chart, and investors are inevitably wondering whether the stock can be expected to recover anytime soon, or if it ...APLS | Complete Apellis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price traded down 3.7% on Wednesday after an insider sold shares in the company. The stock traded as low as $47.20 and last traded at $47.55. 370,506 shares changed hands during trading, a decline of 86% from the average session volume of 2,690,365 shares. The stock […]Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostat...CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Apellis Pharmaceuticals ( APLS 1.62%) and BridgeBio Pharma ( BBIO 0.27%) are prime examples. These two biopharma companies have been storming higher of late in response to high-value catalysts ...APLS GAP FILL APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Underlying @ entry 33.33 I'm a beginner so this is not advice. APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Apellis Pharmaceuticals (APLS). Common Shares. Sell: $47.51|Buy: $48.04|Change: 1.73 (-3.50%).CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Instagram:https://instagram. options trading appscan you invest in chatgpttax exempt bond fund of americatmc stovk WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights. schd top 10 holdingslennar homes resale value WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New ...Dec 1, 2023 · How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold. ai stock list Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...Dec 1, 2023 · 14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price.